Program
Olvimulogene nanivacirepvec
Also written as “GL-ONC1” and “Olvi-Vec”.
Its studies are mostly in Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Peritoneal Neoplasms · Neoplasms · Head and Neck Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genelux | 31 open or running | phase 2since Apr 25, 2016 | Apr 22, 2012 | Feb 2027phase 2 · NCT06463665 |
| Genelux | 20 open or running | phase 2since Sep 20, 2011 | Nov 18, 2008 | none ahead |
| Newsoara HYK Biopharmaceutical (Shanghai) | 11 open or running | phase 2since Jul 2, 2025 | Jul 2, 2025 | Dec 2026phase 2 · NCT07136285 |
Also a collaborator on its studies: Newsoara Biopharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 18, 2008First study: phase 1 study in NeoplasmsNew to GeneluxGenelux · NCT00794131 · 43 enrolled · United Kingdom
- Sep 20, 2011Phase 2 study in Peritoneal NeoplasmsGenelux · NCT01443260 · 9 enrolled · Germany
- Apr 22, 2012Genelux's first study: phase 1 study in Head and Neck NeoplasmsNew to GeneluxGenelux · NCT01584284 · 19 enrolled · United States
- Apr 25, 2016Phase 2 study in Ovarian NeoplasmsGenelux · NCT02759588 · 46 enrolled · United States
- Jun 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungGenelux · NCT06463665 · 142 planned · United States
- Jul 2, 2025Newsoara HYK Biopharmaceutical (Shanghai)'s first study: phase 2 study in SCLC, Extensive StageNew to Newsoara HYK Biopharmaceutical (Shanghai)Newsoara HYK Biopharmaceutical (Shanghai) · NCT07136285 · 27 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in SCLC, Extensive StageNewsoara HYK Biopharmaceutical (Shanghai) · NCT07136285
- Feb 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungGenelux · NCT06463665
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07136285SCLC, Extensive Stage · China | 2 | Recruiting | Newsoara HYK Biopharmaceutical (Shanghai) | Dec 2026 | 27 |
| NCT06463665Carcinoma, Non-Small-Cell Lung · United States | 2 | Recruiting | Genelux | Feb 2027 | 142 |
| NCT02759588Ovarian Neoplasms · United States | 2 | Completed | Genelux | Dec 31, 2021 | 46 |
| NCT01584284Head and Neck Neoplasms · United States | 1 | Completed | Genelux | Jun 2015 | 19 |
| NCT01443260Peritoneal Neoplasms · Germany | 2 | Completed | Genelux | Sep 2014 | 9 |
| NCT00794131Neoplasms · United Kingdom | 1 | Completed | Genelux | Nov 2015 | 43 |
How it is read
Names in the registry
- “GL-ONC1”, 3 entries
- “Olvi-Vec”, 2 entries
- “Olvimulogene nanivacirepvec”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Peritoneal Neoplasms, 1 study
- Neoplasms, 1 study
- Head and Neck Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.